News summaryCNBCNov 16, 2026, 08:07 PM
Eli Lilly makes a deal outside obesity. Plus, another word of caution on Nvidia
aisemiconductors
Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, according to a Calytrix press release. [[fact:fact-1io7o0kkz]] Calytrix is developing an early-stage antibody treatment for rare blood disorders. [[fact:fact-z9358rtf3]] CEO David Ricks said Lilly had completed 40 deals year to date, more than in all of 2025. [[fact:fact-5ko8wcsey]] On Nvidia, the article says it remains unclear whether management will stand by its 70% revenue growth forecast for fiscal 2028. [[fact:fact-try58v8vr]] The article also says Jim recommended trimming some Nvidia shares on Thursday for capital preservation and states that Jensen Huang resigned as CEO. [[fact:fact-3lqqdhp38]][[fact:fact-f4ur1qe21]]